NCT03579966 2024-05-07
Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)
Catalyst Pharmaceuticals, Inc.
Phase 3 Terminated
Clinical Trials
6 trialsNCT03304054 2024-03-12
Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
Catalyst Pharmaceuticals, Inc.
Phase 3 Completed
NCT05919407 2023-06-26
IMPACT-MG
Leiden University Medical Center
Phase 3 Unknown
NCT01377922 2018-01-04
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
Catalyst Pharmaceuticals, Inc.
Phase 3 Completed
NCT01511978 2017-07-11
DAPPER
Jacobus Pharmaceutical
Phase 2 Completed
NCT00004832 2015-03-25
Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome
FDA Office of Orphan Products Development
Phase NA Completed